Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DHR

Danaher's Covid Tailwind Is In Question; Why One Analyst Isn't Worried

Danaher crushed second-quarter expectations Thursday, bolstered by strong Covid testing sales. DHR stock surged higher.

Investors Business Daily

Here's How Much $100 Invested In Danaher 20 Years Ago Would Be Worth Today

Here's How Much $100 Invested In Danaher 20 Years Ago Would Be Worth Today

Danaher (NYSE:DHR) has outperformed the market over the past 20 years by 7.67% on an annualized basis producing an average annual return of 14.78%. Currently, Danaher has a market capitalization of $186.88 billion.

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 9.25% on an annualized basis producing an average annual return of 20.62%. Currently, Danaher has a market capitalization of $184.66 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Here's How Much $100 Invested In Danaher 10 Years Ago Would Be Worth Today

Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 8.15% on an annualized basis producing an average annual return of 19.71%. Currently, Danaher has a market capitalization of $180.36 billion.

Danaher Clocks Q1 Sales Jump Of 12%, COVID-19-Related Restrictions In China To Impact Q2 Sales

Danaher Corp (NYSE:DHR) logged Q1 FY22 adjusted EPS of $2.76, up 9.5% Y/Y, surpassing the estimate of $2.66. Sales increased 12% to $7.7 billion, with 12% non-GAAP core and 8.0% non-GAAP base business core revenue growth, beating the $7.54 billion estimate. Operating cash flow reached $2 billion. Non-GAAP free cash flow reached…

Danaher: Q1 Earnings Insights

Danaher (NYSE:DHR) reported its Q1 earnings results on Thursday, April 21, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

4 Beaten-Down Dividend Growth Stocks to Scoop Up Now

The major benchmark indices posted their best day since mid-March on Tuesday. However, with the International Monetary Fund (IMF) reducing its global economic growth forecast, citing the Russia-Ukraine war and rising inflation as key contributors, the market could remain volatile in the near term. Thus, we think beaten-down dividend stocks…

inkl

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $1000 Invested In Danaher 15 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In Danaher 15 Years Ago Would Be Worth Today

Danaher (NYSE:DHR) has outperformed the market over the past 15 years by 7.05% on an annualized basis producing an average annual return of 14.59%. Currently, Danaher has a market capitalization of $195.51 billion.

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

Here's How Much You Would Have Made Owning Danaher Stock In The Last 15 Years

Here's How Much You Would Have Made Owning Danaher Stock In The Last 15 Years

Danaher (NYSE:DHR) has outperformed the market over the past 15 years by 7.23% on an annualized basis producing an average annual return of 15.22%. Currently, Danaher has a market capitalization of $212.45 billion.

Looking At Danaher's Recent Whale Trades

Looking At Danaher's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Danaher (NYSE:DHR). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

5 No-Brainer Growth Stocks to Buy During the Market Correction

5 No-Brainer Growth Stocks to Buy During the Market Correction

The stock market has been exhibiting immense volatility of late due to escalating economic sanctions on Russia in response to its invasion of Ukraine, inflationary pressures, and supply chain disruptions. However, some growth-focused companies should be able to capitalize on the steady economic recovery this year. Microsoft (MSFT), Alphabet (GOOGL),…

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much

Danaher (NYSE:DHR) has outperformed the market over the past 20 years by 7.58% on an annualized basis.

Thermo Fisher Scientific vs. Danaher: Which Diagnostics & Research Stock is a Better Buy?

Thermo Fisher Scientific vs. Danaher: Which Diagnostics & Research Stock is a Better Buy?

Rising demand for advanced diagnostic devices for predicting the early development of diseases and getting accurate results within less time should drive the diagnostics and research industry’s growth. Given the rising investments in the industry, prominent players in this space, Thermo Fisher (TMO) and Danaher (DHR) should benefit. But which…

Get all your
news in one place.

100’s of premium titles.
One news app.

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years

Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 8.65% on an annualized basis.

Where Danaher Stands With Analysts

Within the last quarter, Danaher (NYSE:DHR) has observed the following analyst ratings:

Danaher Q4 Results Beat Expectations, Clocks 21% Jump In Sales

Danaher Corporation (NYSE: DHR)

Danaher's Earnings Outlook

Danaher (NYSE:DHR) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that Danaher will likely report an Earnings Per Share (EPS) of $2.51.

Get all your
news in one place.

100’s of premium titles.
One news app.

Organisations

Abbott Laboratories

Eli Lilly and Company

rmo Fisher Scientific

KLA Corporation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

258,630 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play